Rituximab for thinking and hand function in advanced MS

This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.

This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.

This trial tests a new cell therapy (NG01) for people with secondary progressive multiple sclerosis whose disability has been worsening. It aims to see if NG01 can slow down or stop that progression.

This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.

This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.

This trial tests rituximab (an immune system medicine) to see if it can reduce OCD symptoms and/or psychosis when there are signs the immune system may be involved. You may be considered if other standard psychiatric treatments have not helped enough and your illness seems relatively recent with possible inflammation clues.